Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

NCT03611556 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT03611556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03611556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
Lead sponsor
MedImmune LLC
Phase
Phase 1/2
Overall status
Completed
Start date
June 21, 2018
Completion date
July 22, 2022
Enrollment
213 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, metastatic pancreatic adenocarcinoma